IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Autor: Sehn, Laurie H. 1, Hubel, Kai 2, Luminari, Stefano 3, Salar, Antonio 4, Wahlin, Bjorn E. 5, Gopal, Ajay K. 6, Bonnet, Christophe 7, Paneesha, Shankara 8, Trneny, Marek 9, Mashegu, Hafsat 10, Lihou, Christine F. 10, Cheng, Lulu 10, Scholz, Christian W. 11
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S385-S386
Databáze: ScienceDirect
Externí odkaz: